Business
Sotera Health Reports Third-Quarter and Year-to-Date 2021 Results
Q3 2021 net revenues of $226 million increased 13%, compared to Q3 2020Q3 2021 net income of $27 million or $0.10 per diluted share, compared to net income of
About this update from Sotera Health Company
[{"type":"text","content":"Q3 2021 net revenues of $226 million increased 13%, compared to Q3 2020Q3 2021 net income of $27 million or $0.10 per diluted share, compared to net income of $0.01 million or $0.00 per diluted share in Q3 2020Q3 2021 Adjusted EBITDA of $117 million increased 16%, compared to Q3 2020Q3 2021 Adjusted EPS of $0.21 improved $0.12 compared to Q3 2020September 30, 2021 total debt of $1.8 billion and total net debt of $1.7 billion; net leverage ratio improved to 3.6xNarrowing full-year 2021 revenue growth outlook to 12% - 14% and full-year 2021 Adjusted EBITDA growth to 13% - 14%Full redemption of $100 million Senior Secured First-Lien Notes CLEVELAND, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the third quarter and first nine months of 2021. Third-quarter 2021 net revenues increased 13.1% to $226 million, compared with $200 million in the same period a year ago. Third-quarter 2021 net income attributable to Sotera Health (“net income”) was $27 million, or $0.10 per diluted share, compared with net income of $0.01 million, or $0.00 per diluted share in the third quarter of 2020. Adjusted EBITDA for the third-quarter 2021 increased 16.1% over the third quarter of 2020 to $117 million. Third-quarter 2021 adjusted earnings per diluted share (“Adjusted EPS”) was $0.21, compared to $0.09 in the third quarter of 2020, an increase of $0.12 per diluted share. Please refer to the section “Non-GAAP Financial Measures” provided later in this release. For the first nine months of 2021, net revenues increased 14.8% to $690 million, compared to $601 million for the same period in 2020. Net income was $81 million, or $0.29 per diluted share for the nine months ended September 30, 2021, compared with net income of $5 million, or $0.02 per diluted share, for the same period last year. First nine months of 2021 Adjusted EBITDA increased 16.2% to $357 million and Adjusted EPS grew by $0.32 to $0.65 compared to the first nine months of 2020. Please refer to the section “Non-GAAP Financial Measures” provided later in this release. “We are very pleased to report solid top-line, net income and Adjusted EBITDA growth...